IP Library Granted Patent US 8,182,987
Granted Patent B2
US 8,182,987 · App. 12/450,155 · Granted May 22, 2012

Probe for visualizing cell-cycle

Assignees: Tokyo Metropolitan Institute of Medical Science; Riken
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,182,987
App. No.
12/450,155
Granted
May 22, 2012
Kind
B2
Abstract

An object of an embodiment of the present invention is to provide a method with which it is possible to easily distinguish a proliferation phase of a cell cycle from a resting phase thereof in real time. The object of the embodiment of the present invention is attained by providing a method for performing phase identification of the cell cycle, the method including: visualizing one or more gene-expression products as markers whose amounts in a cell change in a cell-cycle dependent manner; and detecting the products so as to distinguish the proliferation phase of the cell cycle from the resting phase thereof.

Claims (19)

1. A method for performing phase identification of a cell cycle, the method comprising the steps of:

visualizing, by respectively using markers, at least two or more gene-expression products whose amounts in a cell change in a cell-cycle dependent manner; and

detecting the markers to distinguish a proliferation phase of the cycle from a resting phase of the cycle,

wherein the at least two or more gene-expression products are co-expressed in a cell and comprise

(i) a first gene-expression product comprising a partial fragment of Cdt1; wherein the partial fragment of Cdt1 excludes a Geminin binding site, and increases in a G1 phase and decreases in an S/G2/M phase; and

(ii) a second gene-expression product comprising a partial fragment of Geminin; wherein the partial fragment of Geminin excludes a Cdt1 binding site, and decreases in the G1 phase and increases in the S/G2/M phase;

wherein the first gene-expression product and the second-gene expression product are labeled by the markers, and the markers are different from each other, to visualize the first gene-expression product and the second gene-expression product.

2. The method as set forth in claim 1 , wherein the first gene-expression product is the partial fragment of Cdt1, which partial fragment of Cdt1 is composed of 30th through 120th amino acids of Cdt1.

3. The method as set forth in claim 1 , wherein the second gene-expression product is the partial fragment of Geminin, which partial fragment of Geminin is composed of 1st through 110th amino acids of Geminin.

4. The method as set forth in claim 1 , wherein the markers are a fluorescent protein or a luminescent protein.

5. The method as set forth in claim 1 , wherein the markers are detected over time by carrying out a time-lapse imaging observation on a living cell or a living tissue.

6. The method as set forth in claim 1 , wherein the first gene-expression product is labeled by a red fluorescent protein as the marker, and the second gene-expression product is labeled by a green fluorescent protein as the marker.

7. The method as set forth in claim 1 , wherein the first gene-expression product is a product in which 1 st through 30 th amino acids of Cdt1 are further excluded.

8. The method as set forth in claim 1 , further comprising

introducing into a cell (i) a first gene construct for encoding the first gene-expression product and the marker, and (ii) a second gene construct encoding the second gene-expression product and the marker, and

causing the first and second gene constructs respectively to express the first gene-expression product and marker labeling the first gene-expression product, and the second gene-expression product and marker labeling the second gene-expression product.

9. A method for screening a cell-cycle inhibitor or a drug for a cell cycle-related disease or a method for examining a compound, a drug, or a reagent on its effect and a functional mechanism, the method comprising the steps of:

incubating a cell in the presence of a candidate substance for the cell-cycle inhibitor, a candidate substance for the drug for the cell cycle-related disease, or a reagent for inhibiting specific gene expression; and

performing phase identification of a cell cycle in accordance with a method as set forth in claim 1 , so as to select a candidate substance which has an influence on the cell cycle and/or cell death.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME AND ADDRESS OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 026667 FRAME 0450. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Sep 15, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Reel/Frame 026910/0471 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ERROR IN THE COVER SHEET PREVIOUSLY RECORDED ON REEL 026638 FRAME 0323. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jul 28, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (INCORPORATED FOUNDATION)
Reel/Frame 026667/0450 →
CHANGE OF NAME Recorded Jul 22, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (INCORPORATED FOUNDATION)
Reel/Frame 026638/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2009
From: MIYAWAKI, ATSUSHI; SAWANO, ASAKO; MASAI, HISAO
To: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH; RIKEN
Reel/Frame 023247/0928 →
Priority Claims (1)
JP 2007-068240 · Mar 16, 2007 · national
Continuity (1)
Related Publication 20100100977A1 · Apr 22, 2010